MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. From Wikipedia
The trial success paves the way for regulatory submissions, positioning the drug as the first targeted therapy to modify Sjögren’s disease course.
